MADRID (Reuters) - It is too early to say whether combining Roche's best-selling Avastin cancer drug with the company's experimental immune-boosting medicine MPDL3280A gives a better outcome in fighting tumors.
via Reuters: Health News Read More Here..
No comments:
Post a Comment